Interstitial Lung Diseases Pipeline Analysis: 120+ Companies are Working to Improve the Treatment Space | DelveInsight

DelveInsight's, "Interstitial Lung Diseases Pipeline Insight, 2022," report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in Interstitial Lung Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Interstitial Lung Diseases Pipeline Insights
• DelveInsight's Interstitial Lung Diseases Pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Interstitial Lung Diseases treatment.
• The leading Interstitial Lung Diseases Companies such as AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Cudetaxestat, Boehringer Ingelheim, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Bristol-Myers Squibb, Avalyn Pharma, PureTech Health, Roche, Ark Biosciences, Novartis, Lung Therapeutics, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Taiho Pharmaceutical,Syndax Pharmaceuticals, Metagone Biotech, Galecto Biotech, CSL Behring and AstraZeneca, others are developing novel drug candidates to improve the interstitial lung disease treatment landscape.
• The promising Interstitial Lung Diseases therapies in various stages of development includes AD-214, Abatacept, ATYR1923, Pirfenidone inhalation, RO-0220912, Lung stem cells, Bardoxolone methyl, Pamrevlumab, Deupirfenidone, INOpulse, OATD 01, LT 0011, GDC 3280, Blade Therapeutics, BI 1015550, PRA 023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation, Deupirfenidone, Zinpentraxin alfa, AK 3280, Ianalumab, LTI-03, HZN-825, Tipelukast, ENV-101, PLN-74809, KD025, Setanaxib, TAS-115,Axatilimab, MG-S-2525, GB0139,CSL312 and Saracatinib, others.
• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Interstitial Lung Disease. The therapies under development are focused on novel approaches to treat/improve Interstitial Lung Disease.

Get an overview of the Interstitial Lung Diseases Pipeline landscape @ https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Interstitial Lung Diseases Overview
Interstitial lung disease (diffused parenchymal diseases) are a heterogeneous group of disorders characterized by fibrosis (scarring) of the lungs. These are classified on the basis of histopathological, radiologic and clinical parameters. The classification system used to describe interstitial lung disease categorizes conditions based on clinical, histopathological or radiologic parameters. Clinical classification groups ILD by its causes to help differentiate exogenous or endogenous factors. Interstitial lung disease diseases without identifiable causes get grouped under idiopathic/primary which uses the histopathological and radiological approach as its infrastructure. Many of the subsets of the disease are of unknown etiology. Regardless, they all ultimately share the same manner of development. The morphological changes seen histologically result from a sequence of inflammation within the parenchyma, which is the portion of the lung involved in gas exchange (the alveoli, the alveolar ducts, and the bronchioles). This compartment is the habitat to various proteins and pro-fibrotic elements. These proteins, after repeated cycles of activation, give rise to accumulation of connective tissue. The trigger can be a known agent that deposited within the lung tissues. In some cases, the fibrosis arises spontaneously

Latest Breakthroughs in the Interstitial Lung Diseases Treatment Landscape
• In March 2022, Blade Therapeutics, announced new data from preclinical studies that highlight the differentiating characteristics of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF and other fibrotic diseases. Cudetaxestat (BLD-0409), a non-competitive, reversible inhibitor of autotaxin, has demonstrated direct anti-fibrotic activity and differentiating preclinical and biochemical characteristics which support the potential for a treatment profile in lung and liver fibrosis. Cudetaxestat has been granted orphan drug designations in the treatment of IPF and systemic sclerosis.
• In February 2022, Boehringer Ingelheim announced that the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to its novel investigational therapy, BI 1015550, for the treatment of idiopathic pulmonary fibrosis (IPF). BI 1015550 is an oral, phosphodiesterase 4B (PDE4B) inhibitor with the potential to address both pulmonary fibrosis - an irreversible scarring of lung tissue that negatively impacts lung function and inflammation associated with progressive fibrosing interstitial lung diseases (ILDs)
• In February 2022, Endeavor BioMedicines, announced the completion of a $101 million Series B financing, led by Ally Bridge Group and Avidity Partners.Proceeds will support the advancement of Endeavor's pipeline programs, including ENV-101 (taladegib), a small molecule inhibitor of the PTCH1 receptor in the Hedgehog signaling pathway for the treatment of cancer and idiopathic pulmonary fibrosis (IPF), as well as ENV-201, a potentially best-in-class small molecule inhibitor of ULK1/2 for the treatment of KRAS-driven cancers
• In January 2022, Horizon Therapeutics announced the first patient has enrolled in a Phase IIb pivotal trial to evaluate its development-stage medicine HZN-825, a lysophosphatidic acid receptor 1 (LPAR1) antagonist to treat people with IPF, the most common interstitial lung disease. HZN-825 is an oral selective LPAR1 antagonist that has shown early signs of clinical impact in systemic sclerosis. LPAR1 signaling has been implicated in fibrosis and inflammation, and preclinical and clinical evidence support the antifibrotic potential of LPAR1 antagonism across multiple organ systems, including both lung and skin.
• In November 2021, Biotech Acquisition Company and Blade Therapeutics, Inc. entered into a definitive merger agreement. Upon the closing of the transaction, which is anticipated to occur in the first quarter of 2022, the combined company will be renamed Blade Biotherapeutics, Inc
• In October 2021, Agomab Therapeutics announced that it entered into a definitive agreement under which it will acquire Origo Biopharma S.L., a Spanish clinical-stage biotechnology company developing organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway for the treatment of fibrosis-related disorders.
• In July 2021, FibroGen announced that FG-3019, the Company's human monoclonal antibody against connective tissue growth factor (CTGF), has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF)
• In February 2021, ImmunoMet Therapeutics announced that the US Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for IM156, an investigational Protein Complex 1 inhibitor, being evaluated for idiopathic pulmonary fibrosis (IPF) as well as granting it Orphan Drug Designation.

Interstitial Lung Diseases Emerging Drugs
• DWN12088: Daewoong Pharmaceutical
• LYT-100: PureTech
• BMS-986278: Bristol-Myers Squibb

Discover more about the therapy set to grab substantial Interstitial Lung Diseases treatment landscape @ https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Interstitial Lung Diseases Pipeline Therapeutics Analysis
There are approx. 120+ key companies which are developing the therapies Interstitial Lung Disease. The companies which have their Interstitial Lung Disease drug candidates in the most advanced stage, i.e phase III include Pfizer.

DelveInsight's Interstitial Lung Diseases Pipeline Report covers around 120+ products under different phases of clinical development like-
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Find out more about interstitial lung disease pipeline drugs @ https://www.delveinsight.com/report-store/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Interstitial Lung Diseases Pipeline Report
• Coverage- Global
• Interstitial Lung Diseases Companies- AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Cudetaxestat, Boehringer Ingelheim, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Bristol-Myers Squibb, Avalyn Pharma, PureTech Health, Roche, Ark Biosciences, Novartis, Lung Therapeutics, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Taiho Pharmaceutical,Syndax Pharmaceuticals, Metagone Biotech, Galecto Biotech, CSL Behring and AstraZeneca, and others
• Interstitial Lung Diseases Therapies- AD-214, Abatacept, ATYR1923, Pirfenidone inhalation, RO-0220912, Lung stem cells, Bardoxolone methyl, Pamrevlumab, Deupirfenidone, INOpulse, OATD 01, LT 0011, GDC 3280, Blade Therapeutics, BI 1015550, PRA 023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation, Deupirfenidone, Zinpentraxin alfa, AK 3280, Ianalumab, LTI-03, HZN-825, Tipelukast, ENV-101, PLN-74809, KD025, Setanaxib, TAS-115,Axatilimab, MG-S-2525, GB0139,CSL312 and Saracatinib, and others
• Interstitial Lung Diseases Pipeline Assessment by Product Type
• Interstitial Lung Diseases Pipeline Assessment by Stage and Product Type
• Interstitial Lung Diseases Pipeline Assessment by Route of Administration
• Interstitial Lung Diseases Pipeline Assessment by Stage and Route of Administration
• Interstitial Lung Diseases Pipeline Assessment by Molecule Type
• Interstitial Lung Diseases Pipeline Assessment by Stage and Molecule Type

Table of Content
1. Introduction
2. Executive Summary
3. Interstitial Lung Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Interstitial Lung Disease- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. RO-0220912: Roche
9. Mid Stage Products (Phase II)
10. Daratumumab: Janssen Biotech
11. Early Stage Products (Phase I)
12. BGB 16673: BeiGene
13. Preclinical Stage Products
14. Drug name: Company name
15. Inactive Products
16. Interstitial Lung Disease Key Companies
17. Interstitial Lung Disease Key Products
18. Interstitial Lung Disease- Unmet Needs
19. Interstitial Lung Disease- Market Drivers and Barriers
20. Interstitial Lung Disease- Future Perspectives and Conclusion
21. Interstitial Lung Disease Analyst Views
22. Interstitial Lung Disease Key Companies
23. Appendix

Got Queries? Reach out for more information on the Interstitial Lung Disease Pipeline Report @
https://www.delveinsight.com/report-store/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09193216187
Address: 304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.